Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

NCT00195156 ↗

Phase 1 Terminated Weill Medical College of Cornell University

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out the highest tolerated dose of Depakote in combination with liposome encapsulated all-trans retinoic acid (ATRA-IV) in patients with advanced solid tumor malignancies.

Timeline

Start: 2003-07
Primary completion: —
Completion: —

Publications

Orfali N, O'Donovan TR, Cahill MR, Benjamin D, Nanus DM, McKenna SL, Gudas LJ, Mongan NP. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL). Eur J Haematol. 2020 Mar;104(3):236-250. doi: 10.1111/ejh.13367. Epub 2020 Jan 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Divalproex Sodium	Small molecule	—	—
Background	Tretinoin	Small molecule	—	—

Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies

Summary

Timeline

Publications

Drugs

Indications